About this trial
This application investigates the efficacy of a novel method of neuro-reinforcement based on decoded fMRI activity to reduce fear responses in individuals with phobias (e.g., spiders, snakes). This method works unconsciously in the brain, without the need for participants to endure repeated conscious exposures to their feared stimuli. Fear-related disorders such as specific phobia, post-traumatic stress disorder (PTSD), and other anxiety disorders present a major challenge, as effective treatment options usually involve repeated exposures to feared stimuli, leading to high levels of distress, fear, and panic that can motivate premature treatment termination. Consequently, there is an unmet need for treatment that minimizes subjective discomfort and attrition in order to maximize efficacy. Recent developments in computational neuroimaging have enabled a method that can deliver unconscious exposure to feared stimuli, resulting in effective fear reduction while bypassing a primary cause of treatment attrition. Because this treatment method happens unconsciously in the brain, changes in behavior outcomes are potentially more likely to generalize to different contexts, thereby overcoming a limitation of traditional treatments.
Eligibility criteria
Qualifiers
Individual has normal or corrected to normal vision
Individual has normal or corrected to normal hearing
Individual is competent to understand informed consent
Individual must meet the Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5) diagnostic criteria for specific phobias, animal subtype
Disqualifiers
Individual is unable to fill in consent form correctly
Individual is unable to respond adequately to screening questions
Individual is unable to maintain focus or to sit during assessment
Individual has history of: neurological disease or defect (e.g., stroke, traumatic brain injury, schizophrenia or other psychological disorders, or seizures) Individual has vision problems (including cataracts, amblyopia, or glaucoma) Individual presents with: Obsessive Compulsive Disorder, Substance Use Disorder, Bipolar Disorder, Psychosis, neurologic diagnoses or unstable serious medical conditions
Trial design
Treatments tested in this trial
- Unconscious Neuro-reinforcement
- Unconscious Neuro-reinforcement
- Unconscious Neuro-reinforcement
Treatment groups
Sponsors and collaborators
University of California, Los Angeles
Lead sponsor
National Institute of Mental Health (NIMH)
Collaborator